InVivo Therapeutics Holdings Corp. (NVIV) financial statements (2021 and earlier)

Company profile

Business Address ONE KENDALL SQUARE
CAMBRIDGE, MA 02139
State of Incorp. NV
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1971713332013
Cash and cash equivalents1971713212013
Short-term investments    12  
Restricted cash and investments 00000 
Prepaid expense  0    
Other undisclosed current assets0001001
Total current assets:2071714342115
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment0000112
Prepaid expense11     
Restricted cash and investments000    
Other noncurrent assets0010000
Total noncurrent assets:2310112
TOTAL ASSETS:2291814352217
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2223312
Accounts payable0111111
Accrued liabilities1112201
Debt 000000
Derivative instruments and hedges, liabilities   0127
Deferred revenue and credits000 
Other undisclosed current liabilities0      
Total current liabilities:2323539
Noncurrent Liabilities
Long-term debt and lease obligation11 0112
Long-term debt, excluding current maturities   0112
Operating lease, liability11
Liabilities, other than long-term debt000000 
Deferred revenue and credits000 
Other liabilities0000   
Total noncurrent liabilities:1101122
Total liabilities:34246511
Stockholders' equity
Stockholders' equity attributable to parent196161029176
Common stock0000000
Additional paid in capital247225223194186150106
Accumulated deficit(228)(219)(207)(184)(157)(134)(100)
Total stockholders' equity:196161029176
TOTAL LIABILITIES AND EQUITY:2291814352217

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(9)(11)(13)(25)(24)(22)(18)
Operating loss:(9)(11)(13)(25)(24)(22)(18)
Nonoperating income (expense)0(0)(11)(2)1(11)(1)
Investment income, nonoperating  (12)   (0)
Other nonoperating income (expense)0(1)1(2)1(11)(1)
Interest and debt expense   (0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(9)(12)(23)(27)(24)(33)(19)
Other undisclosed net income   0   
Net loss:(9)(12)(23)(27)(24)(33)(19)
Other undisclosed net income attributable to parent     01
Net loss attributable to parent:(9)(12)(23)(27)(24)(33)(18)
Other undisclosed net income available to common stockholders, basic    0  
Net loss available to common stockholders, diluted:(9)(12)(23)(27)(23)(33)(18)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(9)(12)(23)(27)(24)(33)(19)
Comprehensive loss, net of tax, attributable to parent:(9)(12)(23)(27)(24)(33)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: